Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the transcript. The company is focused on executing existing projects like the Saykha greenfield project and expanding capacities. They have put some smaller projects on hold to manage capex prudently amid rising steel and cement prices. Ankit Patel mentioned not wanting to over-leverage and being cautious about project cost overruns. The strategy includes growing organically via capacity ramp-ups, technology upgrades, and some targeted smaller expansions rather than aggressive acquisitions or new fund

Any current/future capex/capital investment/strategic investment?

The Saykha greenfield project for benzene derivatives and sulphuric acid is ongoing, with trial runs expected in Q2 FY '24 (benzene derivatives) and Q4 FY '24 (sulphuric acid). Some small projects with capex around INR 40 crores are put on hold; to be compensated by investments in better technology for PNCB, ONCB, and sulphuric acid. Revised project cost for Saykha may increase from INR 400 crores to INR 500+ crores, mainly due to steel and shipment price increases. Certain benzene downstream derivative projects like MPDSA, PNA, 2,4-DNCB are on hold, pending outlook evaluation. Focus is on int

Future growth expectations in sales/revenue/volumes?

Bodal Chemicals aims to double dyestuff volumes in the next 2-3 years, particularly leveraging growth in Turkey and surrounding countries. The company plans to diversify from core Dyestuff and Dye Intermediate business towards specialty chemicals like benzene derivatives, which have higher margins (18-25% EBITDA). Chlor Alkali business is expected to ramp up capacity utilization to 90% by January 2023, supporting revenue growth. Saykha greenfield project for benzene derivatives is expected to start trial runs in Q2 FY '24, followed by sulphuric acid trials by Q4 FY '24. Bodal targets I

Future growth expectations in earnings/operating earnings/profits/EPS?

Margins are expected to improve from current 8-12% to around 12-15% in the next 1.5 years as new Greenfield projects (benzene derivatives, sulphuric acid) ramp up to 70-80% utilization. Addition of Chlor Alkali business and integration is driving growth, targeting over INR 1,000 crores turnover from Chlor Alkali and Greenfield projects with higher margin (18-20%) businesses. Consolidated EBITDA margins are anticipated to blend to around 14-15%, reflecting higher-margin specialty chemical segments. Existing core business is steady, but diversification into high entry barrier businesses li

Bodal Chemicals LtdQ2 FY23Chemicals & Petrochemicals

Bodal Chemicals Ltd Q2 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹190P/E: 37.0Market Cap: ₹2.5K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Bodal Chemicals aims to double dyestuff volumes in the next 2-3 years, particularly leveraging growth in Turkey and surrounding countries.
The company plans to diversify from core Dyestuff and Dye Intermediate business towards specialty chemicals like benzene derivatives, which have higher margins (18-25% EBITDA).
Chlor Alkali business is expected to ramp up capacity utilization to 90% by January 2023, supporting revenue growth.
Saykha greenfield project for benzene derivatives is expected to start trial runs in Q2 FY '24, followed by sulphuric acid trials by Q4 FY '24.
Bodal targets INR 400+ crore turnover from Chlor Alkali and INR 500+ crore from benzene derivatives and sulphuric acid combined once projects stabilize.
Overall, company aims for a blended EBITDA margin increase to approximately 14-15% with new integrated product chains and improved cost structures.
Expansion focuses on reducing dependence on volatile dye intermediate business, bringing it down to 30-40% of total revenue.

Margin guidance

Category 1

Margins are expected to improve from current 8-12% to around 12-15% in the next 1.5 years as new Greenfield projects (benzene derivatives, sulphuric acid) ramp up to 70-80% utilization.
Addition of Chlor Alkali business and integration is driving growth, targeting over INR 1,000 crores turnover from Chlor Alkali and Greenfield projects with higher margin (18-20%) businesses.
Consolidated EBITDA margins are anticipated to blend to around 14-15%, reflecting higher-margin specialty chemical segments.
Existing core business is steady, but diversification into high entry barrier businesses like Chlor Alkali, benzene derivatives, and sulphuric acid expected to reduce volatility and enhance profits.
Operational efficiencies from technology upgrades (e.g., Rajpura Chlor Alkali) will lower costs and improve margins.
Subsidiary performance improving, notably in Turkey (Sener Boya), aiding earnings growth.
Overall, management aims for consistent margin expansion and revenue growth through capacity ramp-up and new product integration over the next 2-3 years.

See what Bodal Chemicals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or planned fundraising through debt or equity in the transcript.
The company is focused on executing existing projects like the Saykha greenfield project and expanding capacities.
They have put some smaller projects on hold to manage capex prudently amid rising steel and cement prices.
Ankit Patel mentioned not wanting to over-leverage and being cautious about project cost overruns.
The strategy includes growing organically via capacity ramp-ups, technology upgrades, and some targeted smaller expansions rather than aggressive acquisitions or new fundraising.
Thus, based on the call, no immediate plans for raising funds via debt or equity were indicated.

Order book

The provided transcript and pages from the Bodal Chemicals Limited Q2 FY '23 Earnings Conference Call do not explicitly mention details about the current or expected order book or pending orders. The discussion focuses primarily on business segments, technology upgrades, project updates, financial performance, market dynamics, and strategic initiatives. Therefore, no specific information regarding the current or expected order book or pending orders is available in the given document.

See what Bodal Chemicals Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The Saykha greenfield project for benzene derivatives and sulphuric acid is ongoing, with trial runs expected in Q2 FY '24 (benzene derivatives) and Q4 FY '24 (sulphuric acid).
Some small projects with capex around INR 40 crores are put on hold; to be compensated by investments in better technology for PNCB, ONCB, and sulphuric acid.
Revised project cost for Saykha may increase from INR 400 crores to INR 500+ crores, mainly due to steel and shipment price increases.
Certain benzene downstream derivative projects like MPDSA, PNA, 2,4-DNCB are on hold, pending outlook evaluation.
Focus is on integrated product chains for cost efficiency and higher margins in pharma and agrochemical segments.
No aggressive acquisitions currently; growth planned through greenfield expansions and vertical/horizontal integrations, especially in Chlor Alkali, benzene derivatives, and sulphuric acid.
Several sulfuric acid projects under consideration for forward integration in the next phase.

Track Bodal Chemicals Ltd — get its next earnings analysis in your feed

How does Bodal Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisBodal Chemicals Ltd

Rev 3Mar 1

See where Bodal Chemicals Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Bodal Chemicals Ltd rank in Chemicals & Petrochemicals?

Compare Bodal Chemicals Ltd against every Chemicals & Petrochemicals company (Q2 FY23) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Bodal Chemicals Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →